Drugs / mRNA-1273.213
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-26 | ModernaTX, Inc. | Results Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant q4web.com ↗
Additionally, Moderna announced the publication of neutralizing antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-26 | ModernaTX, Inc. | Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant q4web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927065 ↗ |
| Route | Intramuscular | “Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.” NCT04927065 ↗ |